ii says “time to evolve”
Unilever has faced a tumultuous few weeks as news of its failed £50bn bid to buy GlaxoSmithKline’s consumer health unit came to light along with job cuts, scathing remarks from star fund managers and an activist investor taking a position.
Q4 Boring Money Fund Investor Tracker
Responses due 23 March
Group shows resilience
Deal could be announced this Thursday
More than two years after its botched IPO, WeWork has finally reached the public market at a value just a fifth of what it had aimed for in 2019, and while the firm has demonstrated “signs of improvement”, the real estate company remains marred by investor...